Physician profile
Shemin Gupta
NPI 1609015528
$12,481.25
in general payments reported to CMS, 2019-2025
70 companies · $2,136 in 2025
The $2,136 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $917 · 2021: $864 · 2022: $2,221 · 2023: $2,598 · 2024: $2,396 · 2025: $2,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,031 · Education: $99.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,030.79 |
| Education | $99.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,423.79 | 2019-2025 | |
| Celgene Corporation | $961.83 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $834.61 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| Merck Sharp & Dohme LLC | $797.39 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $669.26 | 2019-2025 | |
| Incyte Corporation | $595.00 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $483.11 | 2019-2025 | Opdivo |
| Abbvie INC. | $435.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $410.62 | 2020-2025 | Ojjaara, Zejula, Blenrep |
| Gilead Sciences, INC. | $393.58 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $380.01 | 2019-2025 | |
| Seagen INC. | $356.46 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Daiichi Sankyo INC. | $354.43 | 2019-2025 | Enhertu, Vanflyta |
| Genentech USA, INC. | $324.22 | 2019-2024 | Tecentriq, Lunsumio, Venclexta |
| Astellas Pharma US INC | $292.74 | 2020-2025 | Padcev, Vyloy, Xtandi |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shemin Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.